Literature DB >> 10235531

Credentialing for breast lymphatic mapping: how many cases are enough?

H S Cody1, A D Hill, K N Tran, M F Brennan, P I Borgen.   

Abstract

OBJECTIVE: To evaluate credentialing issues for sentinel lymphatic mapping for breast cancer. SUMMARY BACKGROUND DATA: The sentinel lymph node (SLN) is defined as the first lymph node receiving lymphatic drainage from a tumor. The SLN accurately reflects the status of the axillary nodes in patients with early-stage breast cancer, and SLN mapping is gaining widespread acceptance. Few of the many published feasibility studies of lymphatic mapping for breast cancer have adequate numbers to assess credentialing issues for this new procedure.
METHODS: Five hundred consecutive SLN biopsies were performed at one institution, over a 20-month period, by eight surgeons, using isosulfan blue dye and technetium-labeled sulfur colloid. The authors reviewed each surgeon's success rate in finding the SLN, and false-negative rate, relative to level of experience with the technique.
RESULTS: Lymphatic mapping performed by an experienced surgeon (surgeon A, B, or C) was associated with a higher success rate (94%) than when it was performed by one with less experience (86%). Ten failed mapping procedures occurred in the first 100 cases. For each of the ensuing 100 cases, there were eight, six, six, and four failed mapping procedures, suggesting that increasing experience does not eradicate failed mapping procedures completely. The false-negative rate among 104 patients in whom axillary dissection was planned in advance was 10.6% (5/47). Most false-negative results occurred early in the surgeon's experience: when the first six cases of every surgeon were excluded, the false-negative rate fell to 5.2% (2/38).
CONCLUSIONS: With increasing experience, failed SLN localizations and false-negative SLN biopsies occur less often. Combined dye and isotope localization, enhanced histopathology, a backup axillary dissection, and judicious case selection are required to avoid the high false-negative rate of one's early experience.

Entities:  

Mesh:

Year:  1999        PMID: 10235531      PMCID: PMC1420817          DOI: 10.1097/00000658-199905000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer.

Authors:  R Pijpers; S Meijer; O S Hoekstra; G J Collet; E F Comans; R P Boom; P J van Diest; G J Teule
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057

Review 2.  Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer.

Authors:  R M Roumen; J G Valkenburg; L M Geuskens
Journal:  Eur J Surg Oncol       Date:  1997-12       Impact factor: 4.424

3.  Sentinel lymphadenectomy in breast cancer.

Authors:  A E Giuliano; R C Jones; M Brennan; R Statman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

4.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Sentinel lymphadenectomy for breast cancer in a community managed care setting.

Authors:  J M Guenther; M Krishnamoorthy; L R Tan
Journal:  Cancer J Sci Am       Date:  1997 Nov-Dec

6.  Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center.

Authors:  B J O'Hea; A D Hill; A M El-Shirbiny; S D Yeh; P P Rosen; D G Coit; P I Borgen; H S Cody
Journal:  J Am Coll Surg       Date:  1998-04       Impact factor: 6.113

7.  Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.

Authors:  P J Borgstein; R Pijpers; E F Comans; P J van Diest; R P Boom; S Meijer
Journal:  J Am Coll Surg       Date:  1998-03       Impact factor: 6.113

8.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.

Authors:  R R Turner; D W Ollila; D L Krasne; A E Giuliano
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

9.  Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.

Authors:  J J Albertini; G H Lyman; C Cox; T Yeatman; L Balducci; N Ku; S Shivers; C Berman; K Wells; D Rapaport; A Shons; J Horton; H Greenberg; S Nicosia; R Clark; A Cantor; D S Reintgen
Journal:  JAMA       Date:  1996-12-11       Impact factor: 56.272

10.  Sentinel node biopsy in breast cancer.

Authors:  J M Barnwell; M A Arredondo; D Kollmorgen; J F Gibbs; D Lamonica; W Carson; P Zhang; J Winston; S B Edge
Journal:  Ann Surg Oncol       Date:  1998-03       Impact factor: 5.344

View more
  19 in total

1.  Practice patterns of lymph-node mapping and sentinel-node biopsy for breast cancer in British Columbia.

Authors:  Boon Chua; Ivo A Olivotto; James C Donald; Allen H Hayashi; Noelle Davis; Conrad H Rusnak
Journal:  Can J Surg       Date:  2003-08       Impact factor: 2.089

Review 2.  New trends in breast cancer management: is the era of immediate breast reconstruction changing?

Authors:  Bohdan Pomahac; Abram Recht; James W May; Charles A Hergrueter; Sumner A Slavin
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

3.  Prevalence and Consequences of Axillary Lymph Node Dissection in the Era of Sentinel Lymph Node Biopsy for Breast Cancer.

Authors:  Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

4.  Structured ultrasonography workshop for breast surgeons: is it an effective training tool?

Authors:  Michael T Law; Ian C Bennett
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

Review 5.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

6.  Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.

Authors:  Igor Langer; Ulrich Guller; Carsten T Viehl; Holger Moch; Edward Wight; Felix Harder; Daniel Oertli; Markus Zuber
Journal:  Indian J Surg Oncol       Date:  2010-08-07

7.  Ex vivo sentinel node mapping in carcinoma of the colon and rectum.

Authors:  J H Wong; S Steineman; C Calderia; J Bowles; T Namiki
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

8.  Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?

Authors:  Nadeem R Abu-Rustum; Fady Khoury-Collado; Neeta Pandit-Taskar; Robert A Soslow; Fanny Dao; Yukio Sonoda; Douglas A Levine; Carol L Brown; Dennis S Chi; Richard R Barakat; Mary L Gemignani
Journal:  Gynecol Oncol       Date:  2009-02-20       Impact factor: 5.482

9.  Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates.

Authors:  Elizabeth R Berger; Karl Y Bilimoria; Christine V Kinnier; Christina A Minami; Kevin P Bethke; Nora M Hansen; Ryan P Merkow; David P Winchester; Anthony D Yang
Journal:  J Surg Oncol       Date:  2018-11-27       Impact factor: 3.454

10.  Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer.

Authors:  Gábor Cserni; Mária Rajtár; Gábor Boross; Mária Sinkó; Mihály Svébis; Béla Baltás
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.